5-Amino-1MQ vs Berberine
preclinical vs Moderate Research
monitor Researched · 90% Both affect metabolic pathways; potential additive glucose metabolism effects.
Molecular Data
5-Amino-1MQ Berberine
Weight — 336.36 Da
Half-life 4-7 hours (3.8h IV, 6.9h oral) ~4 hours
Type Small molecule NNMT enzyme inhibitor Isoquinoline alkaloid (C20H18NO4+)
Key Benefits
5-Amino-1MQ
01 Enhanced NAD+ levels
02 Improved mitochondrial function
03 Better energy metabolism
04 Enhanced cellular repair
05 Improved insulin sensitivity
06 Longevity support
07 Convenient daily oral dosing
Berberine
01 Activation of AMPK, improving cellular energy metabolism and glucose utilization
02 Clinically demonstrated reductions in fasting blood glucose and HbA1c comparable to metformin in some trials
03 Improved lipid profiles with reductions in total cholesterol, LDL cholesterol, and triglycerides
04 Enhanced insulin sensitivity through upregulation of insulin receptor expression
05 PCSK9 inhibition leading to improved LDL cholesterol clearance
06 Gut microbiome modulation favoring beneficial short-chain fatty acid-producing bacteria
07 Anti-inflammatory effects via NF-kB pathway suppression
08 Available over the counter as a dietary supplement without prescription
Dosing Protocols
5-Amino-1MQ
50-100mg oral or 150-500mcg SubQ / Once daily, preferably morning
Conservative starting (mcg protocol) 150-250mcg 1x daily
Conservative standard (mcg protocol) 250-500mcg 1x daily
Study-based (mg protocol) ~350mg (5mg/kg) 1x daily
Berberine
500 mg 2-3x/day / 2-3x daily with meals
Side Effects
5-Amino-1MQ
Generally minimal side effects
Occasional mild GI adjustment
Potential sleep interference if dosed late in day
Berberine
Gastrointestinal distress (diarrhea, cramping, bloating, nausea, flatulence) - most frequent complaint, affecting 10-15% of users, especially at higher doses or without food
Constipation (less common than diarrhea but reported by some users)
Decreased appetite
Mild abdominal discomfort, particularly during the first 1-2 weeks of use
Contraindications
Pregnancy or breastfeeding
Pre-existing metabolic conditions (consult healthcare provider)
Pregnancy and breastfeeding (berberine may stimulate uterine contractions and crosses into breast milk)
Neonates and young children (risk of kernicterus - berberine can displace bilirubin from albumin)
Severe hepatic impairment
Concurrent use with medications that have narrow therapeutic indices metabolized by CYP3A4 (e.g., cyclosporine, tacrolimus) without close medical supervision
Known hypersensitivity to berberine or berberine-containing plants
Research Evidence
5-Amino-1MQ Berberine
Status preclinical Moderate Research
References 3 studies 5 studies
Latest August 2024 2023
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.